GERN earnings: real EPS beat/miss history, analyst consensus Buy, P/E -13.52. Updated 2026-07-23.
Geron (GERN) Research Hub
Geron (GERN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.35 USD (-3.57%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -13.52, market cap 0.90B. This hub links to the full technical, earnings and options research available for GERN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.35 USD (-3.57%) |
| 52-week range | 1.15 USD – 1.65 USD |
| Trend regime | Range |
| 14-day RSI | 41.8 (Bearish) |
| Trailing P/E | -13.52 |
| Market cap | 0.90B |
| Dividend yield | 0.00% |
Available research for GERN
Covered Call on GERN: how it works, illustrative setup around the real 1.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GERN: how it works, illustrative setup around the real 1.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GERN: how it works, illustrative setup around the real 1.35 USD price, max profit/loss, breakeven and when to use it. Educational.
GERN technical analysis: range, last 1.35 USD, RSI 41.8, 52w range 1.15 USD–1.65 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GERN in?
Geron (GERN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GERN in an uptrend or downtrend?
As of 2026-09-11, GERN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GERN's trailing P/E ratio?
GERN's trailing P/E is -13.52, with a market cap of 0.90B. See the earnings research page for full valuation detail.